Spop drives neurodegenerative tauopathy
Active Grant Awarded
- Award ID
- R01AG078374
- Recipient
-
Seattle Institute For Biomedical And Clinical Research UEI DRRKVZVXSND3
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $634,085
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 9% complete
- Place of performance
- Seattle, WA 98108, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute on Aging awarded Seattle Institute For Biomedical And Clinical Research (doing business as Seattle Institute) $634,085 on September 16, 2026, under the Aging Research program (CFDA 93.866) through Grant R01AG078374. The grant funds research into how the E3 ubiquitin ligase adaptor SPOP, a nuclear speckle protein, drives tau-mediated neurodegeneration. The recipient proposes to use both C. elegans and mouse transgenic tauopathy models to test whether SPOP-mediated degradation of substrate proteins alters nuclear speckle dynamics and liquid-liquid phase separation, and thereby modulates pathological tau toxicity. Place of performance is Seattle, WA 98108. The period of performance runs from September 16, 2026 to August 31, 2028. The source identifies no sub-recipients on this award. The program's stated purpose is to support biomedical, social, and behavioral research and training on the aging process, with particular emphasis on preventing and treating Alzheimer's disease and related dementias.
Description
- Abstract
- Aggregated pathological TAU protein constitutes one of the diagnostic hallmarks of alzheimer's disease (ad) and related disorders (ADRD). The molecular mechanisms by which pathological TAU causes dysfunction and degeneration of neurons remains incompletely understood. However, pathological TAU driven neuronal dysfunction and neurodegeneration clearly cause dementia. To investigate how pathological TAU contributes to neurodegeneration in ad and ADRD, we established a transgenic model in C. Elegans for neurodegeneration driven by human TAU aggregation. In our previous work, we identified several genes that control TAU toxicity in C. Elegans including SUT-1, SUT-2, parn-2, SUT-6, ALY-1, ALY-2, and ALY-3; all of these genes share the common property of encoding proteins residing within nuclear speckles. Nuclear speckles are membraneless organelles within the cell's nucleus that function as hubs of RNA processing. Previous translational work from our laboratory and others have shown that ad/ADRD exhibit defects in RNA processing and mislocalization of several nuclear speckle proteins including MSUT2, PABPN1, and SRRM2. We have leveraged our C. Elegans model of tauopathy to begin to dissect the functional role of nuclear speckles in TAU pathology. We found TAU mediated neuronal dysfunction and neurodegeneration can be rescued by loss of a nuclear speckle resident E3 ubiquitin ligase adaptor protein known as spop. We hypothesize spop-mediated degradation of substrate proteins impacts the dynamics and liquid-liquid phase separation of nuclear speckles to modulate the toxicity of pathological TAU. Given the high level of conservation of the nuclear speckle proteins and RNA processing system between mammals and C. Elegans, we propose to utilize both C. Elegans and mouse transgenic tauopathy models to dissect the molecular mechanisms by which spop loss of function protects against TAU neurotoxicity. The specific aims of this project are to: 1) define spop's impact on neuronal nuclear speckle composition and dynamics in tauopathy. 2) identify critical non-degradative CUL3SPOP E3 ligase ubiquitination substrate(S) participating in tauopathy. 3) explore the role of critical CUL3SPOP substrate proteins in both human disease and mouse models of tauopathy. By completing the proposed work, we will develop new molecular understanding of disease mechanisms by which nuclear speckles and the spop protein participate in tauopathy. This work will also provide the first translational effort at understanding whether targeted changes in nuclear speckles can protect neurons from pathological TAU in the mammalian brain.
Quick answers
Who received award R01AG078374?
R01AG078374 was awarded to Seattle Institute For Biomedical And Clinical Research by National Institute on Aging (National Institutes of Health) on September 16, 2026.
How much is award R01AG078374 worth?
$634,085 has been obligated on R01AG078374.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award